Department of General Surgery, Anhui Provincial Hospital Affiliated with Anhui Medical University, 17 Lujiang Road, Hefei 230001, Anhui Province, People's Republic of China.
Med Oncol. 2013;30(2):583. doi: 10.1007/s12032-013-0583-y. Epub 2013 Apr 23.
Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a poor prognosis. Our previous proteomic analysis found apolipoprotein E (ApoE) protein to be up-regulated in the sera of patients with PDAC. In this study, we sought to confirm this finding and investigate the relationship between ApoE and PDAC. We measured ApoE expression in tissues from PDAC patients and normal controls (NC) by real-time PCR, western blot, and immunohistochemistry. Enzyme-linked immunosorbent assay (ELISA) was applied to measure the levels of ApoE and carbohydrate antigen 19-9 (CA19-9) in the sera from patients with PDAC and NC. Real-time PCR and western blots showed that the ApoE mRNA and protein levels were up-regulated in PDAC tissues. The immunohistochemical results revealed that overexpression of ApoE was detected in 43 of 55 (78.2 %) PDAC cases and 3 of 20 (15 %) NC. High levels of ApoE were more likely in PDAC patients with advanced T status and TNM stages (p = 0.023 and p = 0.018, respectively). The ELISA results also confirmed that ApoE levels were elevated in the sera of PDAC patients. The sensitivity and specificity for distinguishing PDAC from NC were 76.2 and 71.4 %, respectively, for ApoE, 66.7 and 85.7 %, respectively, for CA19-9, and 81.0 and 85.7 %, respectively, for their combination. These results suggest that ApoE may be a potential PDAC-related biomarker and alone or in combination with other markers may provide additional information for the diagnosis and clinical management of PDAC.
胰腺导管腺癌 (PDAC) 是一种致命的癌症，预后不良。我们之前的蛋白质组学分析发现载脂蛋白 E (ApoE) 蛋白在 PDAC 患者的血清中上调。在这项研究中，我们试图证实这一发现，并研究 ApoE 与 PDAC 之间的关系。我们通过实时 PCR、western blot 和免疫组织化学测量了 PDAC 患者和正常对照组 (NC) 组织中的 ApoE 表达。酶联免疫吸附试验 (ELISA) 用于测量 PDAC 患者和 NC 患者血清中的 ApoE 和碳水化合物抗原 19-9 (CA19-9) 水平。实时 PCR 和 western blot 显示 ApoE mRNA 和蛋白水平在 PDAC 组织中上调。免疫组织化学结果显示，在 55 例 PDAC 病例中有 43 例 (78.2%) 和 20 例 NC 中有 3 例 (15%) 检测到 ApoE 过表达。T 分期和 TNM 分期较高的 PDAC 患者 ApoE 水平较高 (p = 0.023 和 p = 0.018)。ELISA 结果也证实了 PDAC 患者血清中 ApoE 水平升高。ApoE 区分 PDAC 与 NC 的灵敏度和特异性分别为 76.2%和 71.4%，CA19-9 分别为 66.7%和 85.7%，两者联合分别为 81.0%和 85.7%。这些结果表明，ApoE 可能是一种潜在的 PDAC 相关生物标志物，单独或与其他标志物联合使用可能为 PDAC 的诊断和临床管理提供额外信息。
